Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
- 1 April 2008
- journal article
- phase i-and-clinical-pharmacology
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (10), 1588-1595
- https://doi.org/10.1200/jco.2007.14.0988
Abstract
Purpose: To identify the optimal regimen and dosage of the oral mammalian target of rapamycin inhibitor everolimus (RAD001).Methods: We performed a dose-escalation study in advanced cancer patients administering oral everolimus 5 to 30 mg/wk, with pharmacokinetic (PK) and pharmacodynamic (PD) studies. PD data prompted investigation of 50 and 70 mg weekly and daily dosing at 5 and 10 mg.Results: Ninety-two patients were treated. Dose-limiting toxicity was seen in one patient each at 50 mg/wk (stomatitis and fatigue) and 10 mg/d (hyperglycemia); hence, the maximum-tolerated dose was not reached. S6 kinase 1 activity in peripheral-blood mononuclear cells was inhibited for at least 7 days at doses ≥ 20 mg/wk. Area under the curve increased proportional to dose, but maximum serum concentration increased less than proportionally at doses ≥ 20 mg/wk. Terminal half-life was 30 hours (range, 26 to 38 hours). Partial responses were observed in four patients, and 12 patients remained progression free for ≥ 6 months, including five of 10 patients with renal cell carcinoma.Conclusion: Everolimus was satisfactorily tolerated at dosages up to 70 mg/wk and 10 mg/d with predictable PK. Antitumor activity and PD in tumors require further clinical investigation. Doses of 20 mg/wk and 5 mg/d are recommended as appropriate starting doses for these studies.Keywords
This publication has 27 references indexed in Scilit:
- Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?Oncogene, 2006
- mTOR and cancer therapyOncogene, 2006
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006
- Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimusEuropean Journal Of Cancer, 2006
- mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates AktCancer Research, 2006
- Sirolimus‐associated interstitial pneumonitis in solid organ transplant recipientsClinical Transplantation, 2005
- The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 TranslationCell, 2005
- Phase I's, Photons, and Philosophies: New Tactics for Exploratory Clinical Trials of Concurrent ChemoradiationJournal of Clinical Oncology, 2004
- Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant RecipientsNew England Journal of Medicine, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000